Author Archives: Fredricko

Caregiver Coach: Making sense of dementia

Posted on by

Yes, folks, its nearly spring and that means its time for "Making Sense of Dementia", a free community workshop hosted by me, Frena Gray-Davidson, from 1 to 4 p.m. March 14 at the Ethel BurgerCenter.

Ive been a hands-on Alzheimers and other dementia caregiver for over 20 years now. My boss at the Parks and Rec Department wrote a press release which I am known for being "Irreverent, outspoken and humorous" in my approach to caregiving. I dont know where she got that from, doyou?

Its true I like people with dementia a lot and theyre fine with me if they have dementia. The first person I ever looked after, in Berkeley, Calif., was fine with me. She was a 79-year-old German-Jewish refugee who become an American citizen. At the age of 64, having raised her children and becoming a widow, she went to university for the firsttime.

She got her masters in education. By 74, she was diagnosed with Alzheimers. Which Id never heard of at thatpoint.

I read a bit about Alzheimers, went to a couple of seminars and decided nobody knew what they were talking about, since all the vile things they were saying didnt apply to my person. So I decided to learn Alzheimers fromher.

Thats the way it still is. I learn most from people who have dementia, very little from modern medicine. Actually, in the last 20 years, everything they thought they knew in 1986 has been thrown out of the window. Research has been a dismal failure, though that could change at anymoment.

Meanwhile, theres all of us the caregivers. And this workshop is all about us. You see, this society has been spreading a horrible lie about dementia, which includes Alzheimers and a whole bunch of other dementias. Caregivers have believed that lie. The lie is that we cant do anything until dementia is medicallytreatable.

We can. We can change everything by learning to speak dementia. We can change everything by changing ourselves, what we do, how we do and what we learn. We can have a darn good time with people with dementia. I know you only partially believe me, if at all, so I want to share something withyou.

I got an email last Friday from someone who attended the free community workshop I gave last year at the Faith Presbyterian Church on Choctaw Drive. And Im going to quote it, not only because she says nice things about me You are a gift from God and a virtual lifesaver! Who wouldnt want to hear that aboutthemselves?

But because she talks about how the workshop helped her change and how much her husband with dementia changed because she did. We caregivers dont always understand how much we are the problem. Thats because were too darned busy being caregivers to even ask if theres a better way. Thats where my workshop comes in. Well learn that better way. And well have fun, orelse.

See more here:
Caregiver Coach: Making sense of dementia

Medical staff lack dementia training, new report finds

Posted on by

Their findings have been presented to the authors of a major joint report to be published by the NHS Confederation, Age UK and the Local Government Association.

In one interview, each of which lasted 40 minutes, a consultant appeared to criticise dementia patients because they could not do anything for themselves.

The consultant said: They wont feed themselves, they cant get out of bed themselves, you cant be sure theyre drinking, theyre often incontinent.

The more of that patient group you have, the less care the others are going to get. They are hugely sapping of our scarce resources.

On another occasion observers watched as they saw an elderly man with dementia in tears being reprimanded by a nurse for losing more weight.

The researchers wrote: Not one member of staff offers any comfort or reassurance. The staff nurse tuts and reprimands him for losing more weight.

Prof Gladman, who specialises in care of the elderly, said most of the staff had not been trained to look after dementia sufferers and often make it up as they go along.

He said: Some people said they had never had any training at all. People said they knew the causes of dementia they could tell you microscopic changes that happen to patients but they didnt know what to do. They sort of make it up as they go along.

Here is the original post:
Medical staff lack dementia training, new report finds

Evie Read is an active five-year-old – but ataxia-telangiectasia will rob her of ability to speak and walk while …

Posted on by

Twenty children in the UK are diagnosed with ataxia-telangiectasia every year Progressive condition will slowly rob Evie of her physical abilities. There is no known cure

By Claire Bates

Last updated at 7:50 AM on 29th February 2012

If you saw Evie playing with a group of her school friends, the only difference you might notice is that she is sometimes a little unsteady on her feet.

Tragically her 'wobbly legs' are due to a devastating underlying condition, that will slowly rob the bright blonde girl of her physical abilities while leaving her mentally alert.

The rare disorder known as ataxia-telangiectasia - A-T for short - is a progressive neurodegenerative disease that affects around 20 children in the UK each year. Most youngsters with the condition are wheelchair-bound by the age of 10 and few survive past their 18th birthdays.

Big sister: Evie, 5, (pictured left with her brother Wilf, 3) has a condition that causes progressive disability and premature death. Her parents are campaigning for better awareness of the disease

Evie's father Toby Read, 37, said the day he and his wife Emily had received the diagnosis in September 2011 was the worst of their lives.

'We had read enough to know that it was incurable and that it would do terrible, terrible things to our daughter,' he said.

Original post:
Evie Read is an active five-year-old - but ataxia-telangiectasia will rob her of ability to speak and walk while ...

Autism Awareness/Skyscraper by Demi Lovato (Cover by Nichole337) – Video

Posted on by

25-02-2012 18:49 Thank you for watching our video. Please help raise autism awareness. For more information on Autism, please visit http://www.autismspeaks.org ========= Please visit Nichole's webpage at http Subscribe to Nichole's YouTube Channel: http://www.youtube.com You can follow Nichole on Twitter at: http://www.twitter.com "Like" Nichole337 on Facebook! http://www.facebook.com Get your OFFICIAL Nichole337 merchandise at: nichole337.spreadshirt.com ========= Check out Lou's blog at lous-land.blogspot.com Please watch Lou's video "Fixing" Autism youtu.be You can follow Lou on Twitter twitter.com "Like" Lou's Land on Facebook to get updates on new blog posts and autism news related items! http://www.facebook.com ========= A HUGE thanks to Rob Duffin and Annex Recording! Check out their website: http://www.annexrecording.com Annex on MySpace http://www.myspace.com Annex on Facebook: http://www.facebook.com To book recording time or for general inquiries, you can contact Rob at (801) 597-4007 Annex Recording 12298 South 1840 East, Draper, UT 84020 ========= Big thanks to the amazing and talented Donny Shawn for editing the piece! Visit Donny's website: DonnyShawn.com Contact Donny on Facebook http://www.facebook.com Hook up with Donny on Linkedin: http://www.linkedin.com ========= Thank you to Steve Veasey for the use of his camera!

Read this article:
Autism Awareness/Skyscraper by Demi Lovato (Cover by Nichole337) - Video

Dr. Alex Kolevzon develops treatments to target the core symptoms of autism – Video

Posted on by

28-02-2012 10:23 Dr. Kolevzon, Clinical Director of the Seaver Autism Center, develops new pharmacological treatments to target the core symptoms of autism. Dr. Kolevzon discusses his work with Insulin-like Growth Factor (IGF1), which increases neural communication and may ameliorate issues of learning and memory in individuals with autism. Small trials of IGF1 have begun with children with SHANK3 deletion, a genetic condition held by ~1% of individuals with autism. If successful, Dr. Kolevzon and the Seaver Autism Center will conduct trials with the larger autism population.

Original post:
Dr. Alex Kolevzon develops treatments to target the core symptoms of autism - Video

Research shedding light on why autism is diagnosed later in minority children

Posted on by

WASHINGTON - Early diagnosis is considered key for autism, but minority children tend to be diagnosed later than white children. Some new work is beginning to try to uncover why and to raise awareness of the warning signs so more parents know they can seek help even for a toddler.

"The biggest thing I want parents to know is we can do something about it to help your child," says Dr. Rebecca Landa, autism director at Baltimore's Kennedy Krieger Institute, who is exploring the barriers that different populations face in getting that help.

Her preliminary research suggests even when diagnosed in toddlerhood, minority youngsters have more severe developmental delays than their white counterparts. She says cultural differences in how parents view developmental milestones, and how they interact with doctors, may play a role.

Consider: Tots tend to point before they talk, but pointing is rude in some cultures and may not be missed by a new parent, Landa says. Or maybe mom's worried that her son isn't talking yet but the family matriarch, her grandmother, says: Don't worry Cousin Harry spoke late, too, and he's fine. Or maybe the pediatrician dismissed the parents' concern, and they were taught not to question doctors.

It's possible to detect autism as early as 14 months of age, and the American Academy of Pediatrics recommends that youngsters be screened for it starting at 18 months. While there's no cure, behavioural and other therapies are thought to work best when started very young.

Yet on average, U.S. children aren't diagnosed until they're about 4 1/2 years old, according to government statistics.

And troubling studies show that white kids may be diagnosed with autism as much as a year and a half earlier than black and other minority children, says University of Pennsylvania autism expert David Mandell, who led much of that work. Socioeconomics can play a role, if minority families have less access to health care or less education.

But Mandell says the full story is more complex. One of his own studies, for example, found that black children with autism were more likely than whites to get the wrong diagnosis during their first visit with a specialist.

At Kennedy Krieger, Landa leads a well-known toddler treatment program and decided to look more closely at those youngsters to begin examining the racial and ethnic disparity. She found something startling: Even when autism was detected early, minority children had more severe symptoms than their white counterparts.

By one measure of language development, the minority patients lagged four months behind the white autistic kids, Landa reported in the Journal of Autism and Developmental Disorders.

See original here:
Research shedding light on why autism is diagnosed later in minority children

Autism: It’s In The Eyes

Posted on by

Theres a lot that can be learned about autism by focusing on the eye movements of those who have the developmental disorder, researchers say.

In a new study believed to be the largest of its kind, researchers observed children with and without autism watching movie scenes of kids in age-appropriate social situations.

What they found were striking differences in eye movement between typically developing children and those with autism. Whats more, the researchers noted significant variations depending on where a child with autism fell on the diagnostic spectrum.

The study published in the March issue of the Journal of the American Academy of Child & Adolescent Psychiatry looked at 135 children, including 109 with autism, all around age 10.

Researchers found that when watching the movies, those with autism were more likely to fixate on bodies and inanimate objects rather than a persons eyes or face. Moreover, the degree to which a child focused on something other than a persons face correlated with the level of their disability.

These results help us tease apart some of the vast heterogeneity of the autism spectrum, said Katherine Rice of the University of Maryland, who worked on the study.

Further research could help establish a better understanding of the development of autism, the researchers said.

Read the original post:
Autism: It’s In The Eyes

Autism in minority children often diagnosed later than in white kids, study says

Posted on by

WASHINGTONEarly diagnosis is considered key for autism, but minority children tend to be diagnosed later than white children. Some new work is beginning to try to uncover why and to raise awareness of the warning signs so more parents know they can seek help even for a toddler.

"The biggest thing I want parents to know is we can do something about it to help your child," said Dr. Rebecca Landa, autism director at Baltimore's Kennedy Krieger Institute. Landa is exploring the barriers that different populations face in getting that help.

Her preliminary research suggests even when autism is diagnosed in toddlerhood, minority youngsters have more severe developmental delays than their white counterparts. She said cultural differences in how parents view developmental milestones, and how they interact with doctors, may play a role.

Consider: Tots tend to point before they talk, but pointing is rude in some cultures and may not be missed by a new parent, Landa said. Or maybe a mom is worried her son isn't talking but her grandmother says don't worry cousin Harry spoke late too, and he's fine. Or maybe a pediatrician dismissed the parents' concern, and they were taught not to question doctors.

It's possible to detect autism as early as 14 months of age, and the American Academy of Pediatrics recommends that youngsters be screened for it starting at 18 months. While there's no cure, behavioral and other therapies are thought to work best when started very young.

Yet on average, U.S. children aren't diagnosed until they're about 4 years old, according to government statistics.

And troubling studies show that white kids may be diagnosed with autism as much as a year and a half earlier than black and other minority children, said University of Pennsylvania autism expert David Mandell, who led much of that work. Socioeconomics can play a role, if minority families have less access to health care or less education.

But Mandell said the full story is more complex. One of his own studies, for example, found that black children with autism were more likely than whites to get the wrong diagnosis during their first visit with a specialist.

Early warning signs

Dr. Rebecca Landa, autism director at Baltimore's Kennedy Krieger Institute, is developing videos that show typical and atypical behaviors. Among early warning signs:

Go here to read the rest:
Autism in minority children often diagnosed later than in white kids, study says

Minority kids diagnosed with autism later

Posted on by

Published: Feb. 29, 2012 at 2:08 AM

BALTIMORE, Feb. 29 (UPI) -- Autism does not differ across racial and ethnic groups, but U.S. researchers found some minority children were less likely to receive an early diagnosis.

Dr. Rebecca Landa, director of the Center for Autism and Related Disorders at Kennedy Krieger Institute in Baltimore, investigated whether the symptoms of autism in toddlers play a role in this disparity in diagnosis as part of her work to improve access, education and outreach to minority communities.

Landa and colleagues examined development in 84 toddlers with autism spectrum disorders at an average 26-28 months of age using three standardized instruments that evaluate child development. Children were evaluated by their caregivers using the Communication and Symbolic Behavior Scales Developmental Caregiver Questionnaire and by research clinicians using the Mullen Scales of Early Learning and the Autism Diagnostic Observation Schedule-Generic.

"We found the toddlers in the minority group were significantly further behind than the non-minority group in development of language and motor skills and showed more severe autism symptoms in their communication abilities," Landa said in a statement. "It's really troubling when we look at these data alongside diagnosis

statistics because they suggest that children in need of early detection and intervention are not getting it."

The study was published in the Journal of Autism and Developmental Disorders.

Visit link:
Minority kids diagnosed with autism later

Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case

Posted on by

To: HEALTH, LEGAL AFFAIRS AND MEDICAL EDITORS

WASHINGTON, Feb. 28, 2012 /PRNewswire-USNewswire/ -- This week the Genetics Policy Institute (GPI) joined the Coalition for Advancement of Medical Research (CAMR) in filing an amicus curiae ("friend of the court") brief in the United States Court of Appeals for the District of Columbia Circuit, supporting federal funding for human embryonic stem cell research.

GPI previously filed amicus briefs in the United States District Court and in the Court of Appeals, the latter in collaboration with CAMR and the State of Wisconsin. Both earlier briefs focused on the preliminary injunction in the case.

Bernard Siegel, GPI's executive director, stated, "Our brief supports the District Court's ruling on behalf of the government upholding federal funding for human embryonic stem cell research. We make clear that the NIH complied with the Administrative Procedures Act in adopting stem cell research rules. The brief also focused upon arguments relating to statutory interpretation of the Dickey-Wicker Amendment, maintaining that the government has a complete right to fund research on ethically derived stem cell lines."

GPI's mission is to promote and defend stem cell research and its application in medicine to develop therapeutics and cures for many otherwise intractable diseases and disorders. GPI pursues this mission through production of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, special projects, speaking engagements, online newsletters and strategic collaborations. Among its initiatives, GPI maintains the Stem Cell Action Coalition, an alliance of 75 independent organizations, including patient groups, academic institutes, medical philanthropies and science and medical societies, all supporting stem cell research targeting cures.

SOURCE Genetics Policy Institute

-0-

Read more from the original source:
Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case

Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)

Posted on by

SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell(TM) at the University of Miami Miller School of Medicine. Bioheart recently applied to the FDA to begin trials using adipose derived stem cells in patients with chronic ischemic cardiomyopathy.

"Dr. Joshua Hare and the University of Miami are world leaders in the field of stem cell research," said Mike Tomas, President and CEO of Bioheart. "We look forward to working with these acclaimed experts and bringing the LipiCell(TM) technology to patients in the U.S."

The clinical protocol of the ANGEL trial is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell(TM)) in patients with chronic ischemic cardiomyopathy. Joshua Hare, MD, Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine is the principle investigator of the clinical program.

The Interdisciplinary Stem Cell Institute was established to capitalize on pioneering work in the use of adult stem cells for the repair of malfunctioning human organs. The goal of the Institute is to find new treatments for heart disease, neurological disease, bone disease, diabetes, cancer, eye diseases and other chronic, debilitating, or incurable diseases. University of Miami scientists have led in the development of procedures to extract adult stem cells and have conducted ground breaking research in cell-based therapy for the diseased human heart.

About Bioheart, Inc.

Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Our leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

See original here:
Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)

Baxter Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition

Posted on by

DEERFIELD, Ill.--(BUSINESS WIRE)--

Baxter International Inc. (NYSE:BAX - News) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individuals own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

Chronic myocardial ischemia (CMI) is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. It is often diagnosed based on symptoms of severe, refractory angina, which is severe chest discomfort that does not respond to conventional medical management or surgical interventions.

The prospect of using a persons own adult stem cells to restore and repair blood flow in CMI is a very exciting concept based on a biological regenerative approach, said Norbert Riedel, Ph.D., Baxters chief science and innovation officer. The goals of this phase III trial are aligned with Baxters overall mission to develop life-saving and life-sustaining therapies and it will help us determine if the therapy can make a meaningful difference for CMI patients.

The trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms: treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with CMI, as measured by a change in total exercise capacity at 12 months following treatment. Secondary objectives include reduced frequency of angina episodes at 12 months after treatment and the safety of targeted delivery of the cells.

After stem cell mobilization, apheresis (collecting the cells from the body) and cell processing, participants will receive CD34+ stem cells or placebo in a single treatment via 10 intramyocardial injections into targeted areas of the heart tissue. Efficacy will be measured by a change in total exercise capacity during the first year following treatment and safety data will be collected for two years. Stem cell processing will be conducted in GMP facilities in the United States by Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. To learn more or enroll, visit http://www.renewstudy.com or http://www.clinicaltrials.gov.

This trial is being initiated based on the phase II data, which indicated that injections of patients own CD34+ stem cells may improve exercise capacity and reduce reports of angina episodes in patients with chronic, severe refractory angina.

The phase II trial provided evidence that this strategy, leveraging the bodys own natural repair mechanisms, can improve exercise capacity and reduce chest pain, the first time these endpoints have been achieved in a population of patients who have exhausted conventional treatment options, said Douglas Losordo, MD, vice president of new therapeutic development at Baxter.

CD34+ cells, which are blood-forming stem cells derived from bone marrow, are comprised of endothelial progenitor cells (EPCs), which develop into new blood vessels. Previous preclinical studies investigating these cells have shown an increase in capillary density and improved cardiac function in models of myocardial ischemia.

About Baxter

Read more here:
Baxter Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition

Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical …

Posted on by

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today its Annual "Evening with Medistem" Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell luminaries and pioneers working with Medistem including Dr. Amit Patel, Director of Regenerative Medicine at University of Utah and the first person to administer stem cells into patients with heart failure, Dr. Michael Murphy, Vascular Surgeon at Indiana University and Principal Investigator for Medistem's FDA clinical trial in patients with risk of amputation, and Dr. Alan Lewis, former CEO of the Juvenile Diabetes Research Foundation, advisory board member of Medistem.

In 2007 Medistem discovered an entirely new type of stem cell, the Endometrial Regenerative Cell (ERC). This cell has proven it is a "universal donor" and can be used to treat many more conditions compared to other types of stem cells. The company received FDA clearance to begin clinical trials in September of 2011 for critical limb ischemia, a condition that is associated with amputation. Medistem is also running a Phase II clinical trial for heart failure using the new stem cell. The ERC stem cell does not involve the highly controversial use of fetal tissue, can be produced very economically and administered to the patient in a very simple manner. Medistem is exploring ways to expand clinical trials of its stem cell into other diseases.

"Stem cells and regenerative medicine offer hope in clinical conditions in which hope previously did not exist," said Dr. Stanley Cohan, Head of Neurology at the St Vincent's Hospital, the largest center for treatment of multiple sclerosis in the Pacific Northwest, who will be attending the event. "We are honored in the Portland community to have this distinguished team of accomplished researchers and medical doctors convene here and discuss with us possible collaborations."

"As a long-time member of the Portland academic community, it is exciting to have companies such as Medistem to visit us and share their experiences 'from the trenches' of what it takes to push a cellular drug through the FDA," said Dr. Shoukrat Milipotiv, Associate Scientist in the Division of Reproductive & Developmental Sciences of ONPRC, Oregon Stem Cell Center and Departments of Obstetrics & Gynecology and Molecular & Medical Genetics, and co-director of the ART/ESC core at the Center. He is an internationally recognized researcher in the area of stem cells.

"The Event is an annual celebration to honor our team and collaborators for the successes of the previous year, while at the same time educate the local business and medical community on the latest research on stem cells not just at Medistem but internationally," said Thomas Ichim, Ph.D Chief Executive Officer of Medistem Inc. "2012 is particularly exciting for us due to approvals for two clinical trials, and the initiation of patient treatments within this context."

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and heart failure.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

View post:
Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical ...

Parkinson's Disease (Understanding Disease: Neurology) – Video

Posted on by

26-01-2012 02:51 Get the facts on Parkinson's Disease with this 100%-accurate animated video. Part of Focus Apps' Understanding Disease: Neurology series, the Parkinson's Disease app demonstrates this progressive neurological disorder, which is characterized by tremors, debilitated muscular coordination, weakness, and posture instability. Parkinson's disease is caused by a degeneration of dopamine cells in the movement-control centers of the brain. Explore its causes, classical symptoms, pathophysiology, diagnosis, and treatment. http://www.focusappsstore.net

Here is the original post:
Parkinson's Disease (Understanding Disease: Neurology) - Video

Parkinson’s Disease (Understanding Disease: Neurology) – Video

Posted on by

26-01-2012 02:51 Get the facts on Parkinson's Disease with this 100%-accurate animated video. Part of Focus Apps' Understanding Disease: Neurology series, the Parkinson's Disease app demonstrates this progressive neurological disorder, which is characterized by tremors, debilitated muscular coordination, weakness, and posture instability. Parkinson's disease is caused by a degeneration of dopamine cells in the movement-control centers of the brain. Explore its causes, classical symptoms, pathophysiology, diagnosis, and treatment. http://www.focusappsstore.net

Here is the original post:
Parkinson's Disease (Understanding Disease: Neurology) - Video

Flanders man races against Parkinson’s

Posted on by

MOUNT OLIVE TWP. - A Flanders man who is battling Parkinson's disease will run in a New York City race to raise funds for the Michael J. Fox Foundation for Parkinson's Research.

The man, John Ryan, will run in the NYC Half Marathon on Sunday, March 18, for Team Fox. He hopes to raise $5,000 or more to enable the foundation to continue funding research to find better treatments and a cure for Parkinson's disease, a statement said.

Ryan is an active member and mentor for Team Fox, the foundation's project for supporting grassroots community fundraisers to expand awareness and for Parkinson's research. 

"My awareness to Parkinson's disease came about two years ago when I was diagnosed with Young Onset Parkinson's Disease in August 2010," Ryan said. "As I was soon to find out, Parkinson's is a chronic and progressive disease for which there is no cure at this point.  I realized early on that I had to become pro-active to raise awareness and funds for research before this progresses for myself and the million others diagnosed with Parkinson's."

Continued here:
Flanders man races against Parkinson’s